New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
08:12 EDTPINC, HSPPremier acquires TheraDoc from Hospira for $117M
Premier (PINC) has reached a definitive agreement to acquire TheraDoc, a market leading provider of clinical surveillance software, for $117M in cash, subject to potential purchase price adjustments regarding TheraDoc's actual working capital, cash and indebtedness at closing. The transaction is expected to close in Premier's 1Q15 ending September 30. TheraDoc is a wholly-owned subsidiary of Hospira (HSP). Premier's board unanimously approved the transaction, and applicable antitrust approvals have already been obtained. Based on the trailing twelve months operating earnings provided by TheraDoc, the $117M represents a purchase price multiple in the 10-11 times range. Premier expects the acquisition to be accretive to earnings in the first year following the transaction's completion.
News For PINC;HSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
16:15 EDTHSPHospira: No Form 483 observations issued after inspection of Costa Rica facility
Subscribe for More Information
February 26, 2015
09:41 EDTHSPHospira launches generic Remicade, WSJ says
Subscribe for More Information
February 19, 2015
06:17 EDTHSPHospira Inflectra patient registry reports interim results in treatment of IBD
Data have been presented on the use of Hospira's Inflectra, the world's first approved biosimilar monoclonal antibody, or mAb, at the European Crohn's and Colitis Organisation Inflammatory Bowel Diseases, or ECCO-ibd, conference. Results show a comparable response in patients treated with Inflectra to that expected with the reference product, Remicade, for inducing and maintaining remission in Crohn's disease, or CD, and ulcerative colitis, or UC. These data add to the body of evidence supporting Inflectra's use in inflammatory bowel disease, or IBD. Results presented from the ongoing independent, prospective, nationwide study in Hungary show that for the first 90 patients, treated with Inflectra, reductions compared with baseline were seen in validated measures of disease activity after both two and six weeks of treatment. C-reactive protein, or CRP, a marker of inflammation, was also decreased during induction therapy for UC. Four of the 90 patients showed an allergic reaction to treatment, all of who had previously received anti-TNF medication. The abstract can be found at: P314 Biosimilar infliximab in inflammatory bowel diseases: first interim results from a prospective nationwide observational cohort.
February 18, 2015
08:41 EDTHSPThe Medicines Co. says not giving financial guidance due to Hospira suit
Subscribe for More Information
February 17, 2015
04:47 EDTHSPPfenex price target raised to $16 from $12 at Mizuho
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use